Wells Fargo & Company Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by research analysts at Wells Fargo & Company from $580.00 to $615.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would indicate a potential downside of 5.97% from the stock’s current price.

REGN has been the subject of a number of other research reports. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research report on Monday, August 4th. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Guggenheim raised their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $813.78.

Regeneron Pharmaceuticals Trading Up 0.2%

Shares of REGN opened at $654.04 on Wednesday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $883.15. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $580.56 and a 200-day simple moving average of $564.66. The stock has a market cap of $69.32 billion, a PE ratio of 15.66, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the prior year, the company posted $12.46 earnings per share. The business’s revenue for the quarter was up .9% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. Activest Wealth Management grew its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.